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A modified method of cycled selection was used
to characterize splicing enhancers for exon inclusion
from a pool of -globin-based three exon/two intron
pre-mRNAs with a variable number of random nucleo-
tides incorporated in the internal exon. The pre-mRNAs
generated by this method contained random sequences
ranging from 0 to 18 nucleotides in length. This method
was used to isolate particular splicing enhancer motifs
from a previously enriched pool of extremely diverse
enhancers. After four cycles of selection for mRNA con-
taining the internal exon, a distinct enhancer motif
(GACGACCAGCAG) was highly enriched. This motif
served as strong splicing enhancers in a heterogeneous
exon. We have shown here that the selected enhancer
motif promotes exon inclusion through specific interac-
tion with SRp30. We have also shown that although
present in many of our selected splicing enhancers con-
forming to this motif, a typical purine-rich enhancer
sequence is dispensable for either enhancer activity or
binding with SRp30.
Numerous studies have identified very diverse exonic splic-
ing enhancers that either stimulate constitutive splicing or
regulate alternative splicing (1–10). Transacting splicing fac-
tors, namely the serine/arginine-rich (SR) proteins, have been
shown to interact with exonic splicing enhancers and influence
splicing or exon inclusion (Refs. 3, 6, 7, 11, 12, 13, 14 and
reviewed in Refs. 15, 16). The SR proteins contain a unique RS
domain at the C-terminal region and one or two RNA recogni-
tion motifs at the N-terminal region (reviewed in Ref. 15). The
SR proteins appear to be involved in the selection of both 3-
and 5-splice sites. It has been shown that SR proteins recruit
U2AF65 to the upstream 3-splice site through direct interac-
tion with U2AF35 (17–19). SR proteins also mediate the rec-
ognition of a downstream 5-splice site by U1 snRNP in certain
pre-mRNAs (12, 20, 21). SR proteins may play an important
role in bridging the 5- and 3-splice sites during splicing (18,
22, 23, 24). It has been shown that SR proteins, such as SC35
and SF2/ASF, can simultaneously interact with the U170k and
U2AF35 protein subunits to stabilize the association of the 5-
and 3-splice sites in the early spliceosome (18).
In most studies, the exonic splicing enhancers are identified
as purine-rich sequences present in cellular pre-mRNAs (e.g.
Refs. 3, 6, 10), whereas in recent years certain non-purine-rich
splicing enhancers are also found through cycled selection
(SELEX) from pre-mRNAs containing random sequences (9, 25,
26). Specific RNA sequences with high affinity for purified SR
proteins have been identified as a short consensus selected
from pools of random sequences and shown to serve as splicing
enhancers (7, 27, 28). In these studies, the RNA consensus for
binding each SR protein ranges from 6 to 10 nucleotides in
length (reviewed in Ref. 16). However, when assayed for splic-
ing enhancer activity, both the selected consensus and its
flanking sequences or multiple copies of the consensus must be
inserted in pre-mRNAs. This raises the question of whether
each selected consensus alone is the complete binding motif for
the SR protein and is sufficient as a splicing enhancer. Our
previous study has obtained very efficient yet extremely di-
verse splicing enhancers that stimulate exon inclusion in a two
intron/three exon pre-mRNA, DUP184 (9). Such diversity was
likely because of the fact that no consensus sequences could be
derived from limited sequencing data of highly complex pool of
enhancers enriched through various mechanisms of action. We
have attempted to specifically isolate individual motifs through
selectively enriching subpopulations of the whole pool. We hope
that such subpopulations with greatly reduced sequence com-
plexity would yield one or more enhancer motifs. In the present
investigation, we have developed a unique method to directly
isolate and identify minimum enhancer motifs from particular
subpopulations of enhancers containing variable number of
random nucleotides. We have identified RNA motifs that have
strong enhancer activity and specifically interact with SRp30.
EXPERIMENTAL PROCEDURES
Primers, Templates, and Plasmids—The materials and methods
used for selection of exon inclusion enhancers were essentially as pre-
viously described (9), except that a newly designed primer (primer 7,
5-GCCATTCGTAATGTCTGCCCATTCTGCT-3) replaced the previ-
ously used primer 6. The positions of both primers are shown in Fig. 1B.
For this study, the pool of sequences obtained by five cycles of in vitro
splicing and reverse transcriptase-PCR1 from the previous study was
initially used as the starting material for PCR with primers 7 and 5 to
generate fragment R’. The full-length DNA template was obtained by
overlapping extension with two overlapping halves of the template
obtained by PCR with primers 1 and 2, fragment R, and primer 4,
respectively. After an additional four cycles of selection the recon-
structed DNA template was ligated into pSP64 vector through HindIII-
BamHI restriction sites (Promega). The plasmid DNA was used to
transform DH5 Escherichia coli cells, and individual clones were
sequenced.
Templates of LP4.19R, 4.7R, 4.7RA, 4.7RB, 4.7RC, and 4.7RD for
transcription were constructed via site-directed mutagenesis from two
halves. To construct the 5-halves of the templates, DUP184REV plas-
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mid2 was subjected to PCR with primer 1 (Fig. 1A and Ref. 9) and the
primers 5 4.19 (CTGCTGCTCCTCGTCGTCTTATCCGCCAAGTACA-
A), 5 4.7 (CAGTTCTGCTGAGTCGTCTTATCCGCCAAGTACAA), 5
4.7A (CAGTTCTGCTGACTGCTGTTATCCGCCAAGTACAA), 5 4.7B
(CAGTTCTGGTGAGTGGTCTTATCCGCCAAGTACAA), 5 4.7C (CAG-
TTCTGGTGACTGGTGTTATCCGCCAAGTACAA), 5 4.7D (GGAGGG-
CACAGTTAGTCGTCTTATCCGCCAAGTAC), respectively. The 3-
halves of the templates containing an overlapping sequence with the
5-half were obtained by PCR with primer 4 and the primers 3 4.19
(GACGACGAGGAGCAGCAGACTGTGCCCTCCATGC), 3 4.7 (GACG-
ACTCAGCAGAACTGTGCCCTCCATGC), 3 4.7A (CAGCAGTCAGCA-
GAACTGTGCCCTCCATGC), 3 4.7B (GACCACTCACCAGAACTGTG-
CCCTCCATGC), 3 4.7C (CACCAGTCACCAGAACTGTGCCCTCCAT-
GC), 3 4.7D (GACGACTAACTGTGCCCTCCATGC). The full-length
templates were obtained by overlapping extension of the two halves
through PCR, digested with HindIII and BamHI and were cloned into
the pSP64 vector.
In Vitro Transcription, Splicing, and Electrophoresis—To prepare
pre-mRNAs for in vitro splicing, the plasmids were linearized with
BamHI and transcribed by SP6 RNA polymerase (9, 29). The HeLa
nuclear extract was prepared as described (30). RNA splicing was
carried out in a mixture of around 10 g/l HeLa nuclear extract,
50,000 cpm of 32P-labeled pre-mRNA and splicing buffer containing
1.3% polyvinyl alcohol, 1.5 mM ATP, 10 mM creatine phosphate, and 3
mM MgCl2 (31). The splicing products were extracted with phenol and
precipitated in ethanol and resolved on an 8% polyacrylamide, 7 M urea
gel in 1 Tris-borate-EDTA. The 32P-labeled RNA probes used for filter
binding and UV cross-linking assays were transcribed in vitro by T7
RNA polymerase (Promega) from synthesized DNA templates and four
different [-32P]NTP following the manufacturer’s instructions and pu-
rified on a 10% polyacrylamide, 7 M urea gel.
Double Filter Binding, UV Cross-linking, and Immunoprecipita-
tion—For the binding reaction, 3 g/l of HeLa nuclear extract, 0.2
g/l of tRNA, and splicing buffer were incubated on ice for 20 min with
30,000 cpm of 32P-labeled RNA probes in a total volume of 10 l. The
mixtures were added with 40 l of splicing buffer before loaded onto a
set of stacking nitrocellulose and Nylon membranes (Schleicher &
Schuell) pre-equilibrated with splicing buffer and mounted on a 96-well
manifold (Schleicher & Schuell). After passed through the filters by
vacuum, the membranes were washed once with 50 l of splicing buffer.
The membranes were separated and autoradiographed on a phospho-
rimager. For UV cross-linking, protein/RNA mixtures in a volume of 10
l as above were irradiated with UV (short wave range) at about 7
milliwatts/cm2 on ice with a UV transilluminator (Fotodyne) for 10 min.
For immunoprecipitation, the samples from UV cross-linking were di-
luted with 40 l of IP buffer (20 mM pH 7.9 Hepes, 150 mM KCl, 20%
glycerol, 1 mM dithiothreitol, 1% Triton X-100, 0.1% Nonidet P-40, and
0.2 mM EDTA) and precipitated with 4.8 g of monoclonal antibody 1H4
specific for SR proteins (BAbCO) and 4 l of flurry protein G-Sepharose
beads (Amersham Pharmacia Biotech) at 4 °C for overnight. The beads
were washed twice with 50 l of IP buffer. The precipitated proteins
were treated with 5 g of RNase A for 15 min at 37 °C, dissolved in SDS
loading buffer, and resolved on a 10% polyacrylamide/SDS gel. The gel
was dried before autoradiography.
Depletion of SRp30 through RNA-based Affinity Chromatography—
Equal amounts of HeLa nuclear extract were loaded onto columns
containing streptavidin-agarose beads (Amersham Pharmacia Biotech)
without RNA or tagged with RNA containing the enhancer LP4.7 (5-
GACGACUCAGCAGCCAGAGGUCGAUGUACU-3), LP4.19 (5-GAC-
GACGAGGAGCAGCAGCCAGAGGUCGAUGUACU-3), or the equiva-
lent DUP184 sequence (5-GUAUACAGAAUAGCAGAAUGCCAGAGG-
UCGAUGUACU-3). The RNA tags were appended to the beads by
hybridizing them to a biotinylated 2-O-methyl-RNA oligonucleotide
(5-biotin-AGUACAUCGACCUCUGG-3) that is complementary to the
extended 3 common sequence of the RNA tags. The flow-through ex-
tract samples were collected and adjusted to equal volumes with Buffer
D (30) and tested for splicing activities.
Autoradiography and Imaging—Autoradiography was either pro-
cessed with Fuji x-ray film or by a Storm 840 phosphorimager (Molec-
ular Dynamics). The efficiency of internal exon inclusion was quanti-
tated by densitometry of the autoradiograms using the NIH Image 1.47
software or directly quantitated on a phosphorimager. The percentage
of products with an included internal exon relative to the sum of the
total mRNA products was calculated.
RESULTS
Refinement of Sequence Motifs from a Complex Pool through
Selective Amplification—Through an iterated enrichment proc-
ess, we have obtained largely diverse exonic splicing enhancers
that promote exon inclusion during splicing of a human -glo-
bin-based pre-mRNA (9). We have then attempted to isolate
particular splicing enhancer motifs by selectively amplifying
homologous sequences from the complex pool of enhancers. As
the starting material for the experiments described in this
study, we used the previously obtained pre-mRNA library con-
taining a 20-nt random sequence in an internal exon (DUP184
cycle 5 in Ref. 9) to generate a less diverse pre-mRNA library.
Different from the previous primer 6, which was completely
complementary to the exon sequence flanking the random 20
nt, we extended the 3-end of primer 6 by adding a 10-nt leader
of the original DUP184 sequence, which showed no splicing
enhancer activity. When annealed to the exon, this 10-nt leader
of the modified primer (primer 7, Fig. 1B) would overhang from
the adjacent flank into the random 20 nt and freely hybridize
with any short complementary sequence present within or out-
side the random 20 nt of pre-mRNAs (Fig. 1B). If the DUP184
cycle 5 pool contains sequences complementary to the 3-end of
primer 7, they would be amplified through PCR and therefore
become templates for the new pre-mRNA library.
To test this concept, the DNA template of DUP184 cycle 5
was subjected to PCR with primers 5 and 7, and the amplified
fragment (R in Fig. 1A) was used to reconstruct the full-length
DNA template for pre-mRNA (Fig. 1A). Sequencing of 30 indi-
vidual clones isolated from the reconstructed pool (Pool LP0)
showed that primers 5 and 7 have indeed amplified sequences
from the DUP184 cycle 5 pool. In these clones, the random
sequences were greatly varied in length with a roughly even
distribution from 0 to 18 nt (Fig. 1C), although the “in-frame”
random sequences should have been 10 nt in length. Only 5
clones contained random 10 nt (clones LP0.4, LP0.8, LP0.11,
LP0.28, LP0.29) while three clones contained random se-
quences longer than 10 nt, and the majority had shorter or no
random sequences. Surprisingly, no clones with truncations
outside the random region were found through the preliminary
sequencing. We conclude that the variable number of random
nucleotides in different clones resulted from annealing of the
3-leader of primer 7 at variable positions within the random
region of the internal exon during PCR.
Characterization of Splicing Enhancer Motifs—The pool of
LP0 pre-mRNAs was subjected to four cycles of selection with
previously described methods (9). Individual pre-mRNAs from
the pool LP0 and final pool LP4 were tested for splicing activ-
ity. Nearly all LP0 pre-mRNAs showed less than 40% inclusion
of the internal exon in splicing probably because of the disrup-
tion of previously selected splicing enhancers during recon-
struction of the pre-mRNA pool (data not shown). In contrast,
the majority of the LP4 pre-mRNAs showed much greater exon
inclusion (Fig. 2A), indicating that the reconstruction had iso-
lated and further enriched a subpopulation of splicing enhanc-
ers from the pool of extremely diverse pre-mRNAs.
Analysis on the sequences of 45 LP4 clones showed that the
selection had narrowed down the length distribution of the
random sequences. Clones with fewer than 6 randomized nt
were eliminated from the pool LP4 during selection, and thirty-
five of the clones (78%) contained 10  2 random nt (Table I).
We had divided the sequences into three groups based on
homology. In Group I, 5 clones (Fig. 2B, clones LP4.17, LP4.19,
LP4.27, LP4.37, LP4.44) contained an identical 12 nt sequence,
ACGACGAGGAGC. Unexpectedly, when combined with the 5-
and the 3-flanking nucleotides, this redundant sequence
formed a symmetrical motif gACGACGAGGAGCagcag (the2 Z. Dominski and R. Kole, unpublished data.
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flanking nucleotides are in lowercase). Sequences of this group
indicated the consensus [gACGACCagcag] with a variable
purine-rich core in most clones, although a few contained no
purine-rich core (e.g. LP4.7, Fig. 2A). Fourteen clones from pool
LP4 contain this motif, or 31% of the pool, although only 1 clone
(LP0.14) from pool LP0 matches this consensus, or 3.3%. There-
fore, this motif has been enriched approximately 10-fold from
pool LP0 to LP4. In Group II, sequences point to the consensus
[gACpurine-richcag] with a variable purine-rich core in the
middle (Fig. 2A). There are 21 clones in LP4 in this group, or
46.7% of the pool, while 13 clones in pool LP0, or 43.3%.
Therefore, there is nearly no enrichment for this motif from
pool LP0 to LP4. Group III contains both purine-rich and non-
purine-rich sequences without a consensus. This study has
focused on investigating whether the Group I motif represents
strong splicing enhancers and whether the symmetrical struc-
ture per se plays a role in exon inclusion.
Because the purine-rich core GAGGAG of LP4.19 conforms to
the exon-splicing enhancer GARGAR present in other
pre-mRNAs (e.g. Ref. 32), we attempted to determine the con-
tribution of the purine-rich core to splicing enhancer activity.
As a comparison, we used LP4.7, which lacks the purine-rich
core but has the same motif and a single uridine present at the
center (Fig. 2B). As shown in Fig. 3, the LP4.19 pre-mRNA
included the internal exon very efficiently during splicing
(lane 4), and the LP4.7 pre-mRNA showed only slightly lower
exon inclusion (lane 5). This indicates that the motif
[GACGACCAGCAG] largely retained enhancer activity in
the absence of the purine-rich core.
To examine the effect of the symmetrical structure of the
motif on splicing enhancer activity, LP4.19 and LP4.7, and
several modified LP4.7 sequences either retaining or lacking a
symmetrical structure (Fig. 3, LP4.7RB, LP4.7RA, and
LP4.7RC), as well as the sequence corresponding to the 5
portion of the motif (GACGAC, LP4.7DR) were introduced via
site-directed mutagenesis to the equivalent positions in the
internal exon of the construct DUP184REV, in which a major
portion of the internal exon was in reverse orientation relative
to that of DUP184. As shown in Fig. 3, while the original
DUP184REV pre-mRNA included the middle exon even less
efficiently than DUP184 (Fig. 3, lanes 3 and 2, respectively),
the LP4.19 and LP4.7 sequences placed in DUP184REV en-
hanced exon inclusion as efficiently as in DUP184 (lanes 4–7),
indicating that they retained splicing enhancer activity in a
FIG. 1. A, scheme for generating length polymorphism of randomized nucleotides. Open boxes, exon sequences; hatched box, randomized
sequence; thin lines, introns; SP6 box, SP6 promoter; heavy lines, PCR primers. The PCR template represents the sequence library obtained by 5
cycles of selection described previously (cycle 5, Ref. 9). Primer 7 corresponds to the sequence indicated in Fig. 1B. The 10 nucleotides from its
3-end are able to hybridize with complementary stretches present within the random sequence of the individual clones. PCR with primers 5 and
7 generated a product of 150 nt (R), which was used with primer 4 in subsequent PCR to generate the 3-half of the DNA template. This fragment
combined with the product of PCR with primers 1 and 2 was further amplified with primers 1 and 4 leading to the full-length DNA template used
subsequently for in vitro transcription of pre-mRNA. B, sequence of the internal exon of DUP184 pre-mRNA. The randomized sequence is indicated
by N and is boxed. Arrows indicate primers 5 and 7, which were used to alter the length of the randomized sequence, as shown in A and throughout
the selection cycles to reconstruct the DNA templates. Primer 6, which had been used previously (9) to obtain a 20-nucleotide, fixed length random
sequence is shown for comparison. C, sequence of the randomized region from 30 individual LP0 clones. The central portion of the figure shows
random sequences of variable length. The constant flanking sequences are shown for clone LP0.3. Dashes indicate deletions within the expected
10 random nucleotides.
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different sequence context. Deletion of the right-half portion of
the motif drastically reduced its enhancer activity (lane 8),
indicating that the 3 portion of the motif (CAGCAG) is also
required for the splicing enhancer activity even though the 3
portion by itself has no splicing enhancer activity. In addition,
it appears that the particular selected sequence rather than the
symmetrical structure per se contributed to the splicing en-
hancer activity, as nucleotide substitutions either retaining or
disrupting a symmetrical structure also led to dramatically
reduced exon inclusion (lanes 9–11).
Interaction of the Selected Splicing Enhancer Motif with SR
Proteins—To test whether the selected splicing enhancer mo-
tifs interact with protein factors in the HeLa nuclear extract,
we used a double filter binding method (33). Internally 32P-
labeled RNA probes of the selected motifs (LP4.19 and LP4.7)
and several mutated sequences lacking the motifs (LP4.19A,
LP4.7A, LP4.7B, LP4.7C, and LP4.7D), as well as the equiva-
lent DUP184 sequence were incubated with HeLa nuclear ex-
tract. The mixtures were passed through the stacking nitrocel-
lulose and nylon filters. As shown in Fig. 4A, around 60% of the
input LP4.19 and LP4.7 RNA probes were present in RNA-
protein complexes and bound to the nitrocellulose membrane,
while only 9–17% of the input DUP184, LP4.19A, LP4.7A,
LP4.7B, LP4.7C, and LP4.7D RNA probes were retained on the
nitrocellulose membrane. To determine whether the selected
splicing enhancers interact with SR proteins, a mixture of fully
internally 32P-labeled RNA probes (DUP184, LP4.19, LP4.19A,
LP4.7, 4.7A, LP4.7B, LP4.7C, and LP4.7D) and HeLa nuclear
extract were irradiated with UV after incubation. The cross-
linking products were immunoprecipitated with the mono-
clonal antibody 1H4 that recognizes all members of the SR
protein family. The immunoprecipitates were treated with
RNase before being resolved on an SDS-polyacrylamide gel for
autoradiography. As shown in Fig. 4B, both LP4.7 and LP4.19
probes were cross-linked to SRp30. In contrast, mutations that
changed the LP4.19 and LP4.7 enhancer motifs (LP4.19A,
LP4.7A, B, C, and D) abolished their interaction with SRp30.
Therefore, the specific interaction of the selected LP4.7 and
LP4.19 motifs and SRp30 strongly correlates with their splic-
ing enhancer activity. Consistent with its lack of splicing en-
hancer activity, the DUP184 sequence was not recognized by
SR proteins. In separate experiments, depletion of the SRp30
from HeLa nuclear extract by affinity columns tagged with
either the LP4.7 or LP4.19 RNA motifs has led to the inhibition
of splicing of the LP4.7 and LP4.19 pre-mRNAs, while deple-
tion with the DUP184 RNA sequence showed nearly no effect
on splicing (data not shown). It is possible that the SRp30 is an
essential splicing factor or that by binding to exonic enhancers
the SRp30 interacts with other general splicing factors in the
early spliceosome, so that depletion of the SRp30 also removed
these general splicing factors and abolished the splicing activ-
ity of the nuclear extract.
DISCUSSION
Identification of Particular Splicing Enhancer Motifs from a
Complex Pool—Selection of particular RNA molecules from a
random sequence library provides a powerful tool for identify-
ing binding motifs or for selecting new catalysts (34–37). Be-
cause the exact number of nucleotides involved in binding or
catalysis is mostly unknown prior to selection, the number of
residues to be randomized is in most cases arbitrarily chosen.
The “consensus” sequences identified by such method are the
homologous regions present among the multiple selected win-
ners but may not necessarily represent the complete motifs for
binding or function. In most cases, sequences outside the con-
sensus must also be included for proper activity. Our study
shows that complete sequence motifs can be directly identified
FIG. 2. A, splicing of the pre-mRNAs isolated from pool LP4. Splicing
of control pre-mRNAs which include (DUP184AG) or exclude (DUP184)
the internal exon (Ref. 2) is shown in lanes 1 and 2, respectively. Lanes
3–15, splicing of pre-mRNAs transcribed from individual LP4 clones
indicated at the top of the figure. The structure of splicing products and
intermediates is shown on the right. B, sequence of the randomized
region of 45 individual LP4 clones. The number of nucleotides in the
randomized region ranges from 6 to 18. Clones 4.17, 4.19, 4.27, 4.37,
and 4.44 contain an identical sequence. The missing clone numbers (e.g.
4.13) are due to non-readable sequencing gels. The consensus motifs are
indicated in bold face and flanking sequences are in lowercase.
TABLE I
Length distribution of the selected sequences
Pool LP0 LP4
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from a complex pool enriched for multiple targets by isolating a
subpopulation of sequences of variegated length. This method
uses a primer extended from the fixed flanking region to isolate
and amplify a subpopulation that shares a common short se-
quence through annealing with the extended 3-leader of the
primer in PCR. Consequently, a library with variable number
of nucleotides but a common short sequence in the random
region is obtained. We believe that by using PCR primers with
various leader sequences different subpopulations of the whole
pool, which represent various regions of the sequence space,
may be isolated and individually enriched to a further extent.
As a result, multiple sequence identities from selections for
very complex targets may be rapidly determined. Although in
our study short sequences recognized by the 3-leader of the
selective primer are present in certain selected enhancers, they
do not have to be part of the enhancer motifs.
In search for unknown splicing enhancers, RNA sequences
have been selected against purified SR proteins through bind-
ing affinity (7, 27, 28). In these studies, however, the splicing
enhancer activity has not been involved in selection mecha-
nism. Not surprisingly, all selected high-affinity binding se-
quences are not splicing enhancers (e.g. Ref. 28). We and others
FIG. 3. Splicing enhancer activity of LP4.19 and LP4.7 motifs
and their mutants in a heterogeneous pre-mRNA. The symmetri-
cal LP4.19 and LP4.7 sequences as well as their mutated sequences
(listed below) were inserted into the DUP184REV construct via site-
directed mutagenesis, and pre-mRNAs transcribed from these con-
structs were spliced. Lanes 1–3, splicing of control DUP184AG,
DUP184, and DUP184REV pre-mRNAs, respectively; lanes 4 and 5,
splicing of LP4.19 and LP4.7 pre-mRNAs, respectively; lanes 6 and 7,
splicing of LP4.19R and LP4.7R pre-mRNAs; lane 8, splicing of
LP4.7RD pre-mRNA, which has a truncated LP4.7 motif. Other altered
LP4.7 sequences, which either retain (4.7RB) or eliminate (4.7RA and
4.7RC) the symmetrical LP4.7 motif were also inserted into
DUP184REV. Lanes 9–11, splicing of 4.7RA, 4.7RB, and 4.7RC pre-
mRNAs, respectively.
FIG. 4. The splicing enhancer motif is specifically recognized
by SRp30. A, double filter binding assay with HeLa nuclear extract and
fully internal 32P-labeled RNA probes DUP184, LP4.19, LP4.19A,
LP4.7, LP4.7A, LP4.7B, LP4.7C, and LP4.7D (sequences are listed
below). RNA/protein complexes are retained on the nitrocellulose mem-
brane (top) whereas the unbound RNA probes pass through the nitro-
cellulose membrane and bind to the nylon membrane (below). The
nitrocellulose retention was calculated as the percentage of counts of
the RNA probes on nitrocellulose membrane out of the sum on both
membranes. B, UV cross-linking of the 32P-labeled RNA probes with SR
proteins. Fully internal 32P-labeled RNA probes (listed on top of the gel)
and HeLa nuclear extract were irradiated by UV on ice. The cross-
linking products were immunoprecipitated with the monoclonal anti-
body 1H4 specific for SR proteins and treated with RNase. The immu-
noprecipitates were dissolved in SDS loading buffer and resolved on a
10% polyacrylamide/SDS gel. The gel was dried for autoradiography.
The protein molecular size markers are on the right.
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have used function-based SELEX to simultaneously select var-
ious exonic splicing enhancers regardless of the mechanism of
action (9, 25, 26, 38). Although the in vitro selections have
generated a much broader spectrum of splicing enhancers than
those identified in vivo, it is difficult to identify particular
motifs based on limited sequencing data due to the presence of
extremely diverse enhancers (9, 26). In this study we have
developed a unique method to isolate a motif through selective
amplification of a subpopulation from a complex pool of splicing
enhancers, which is shown to specifically interact with SRp30.
We believe that with our method, various motifs recognized by
different splicing factors can be isolated from a very complex
pool of enhancers when the identity of particular motifs cannot
be revealed through preliminary selection.
A subpopulation of exonic enhancers isolated from our pre-
viously enriched pool of splicing enhancers contained a variable
number of random nucleotides ranging from 0 to 18. After a few
additional rounds of selection, the length of the random se-
quences in 45 randomly chosen clones ranged from 6 to 12
nucleotides (Table I). The pre-mRNAs with fewer or no random
sequences (e.g. LP0.3, LP0.7, and LP0.9) were eliminated
through further selection. The progress of selection is associ-
ated with increasing splicing enhancer activity of the pool and
enrichment of the most efficient splicing enhancers, e.g. LP4.19
and LP4.7 (Figs. 2 and 3). It is unlikely that enhanced exon
inclusion is due to the removal of a negative element from exon
as observed in other studies (39–41), because replacement of
the original DUP184 sequence with either random sequences
prior to selection or various defined sequences largely main-
tained predominant exon skipping (9).3 Therefore we conclude
that specific splicing enhancers have been enriched through
the cycled selection employed in our studies.
Splicing Enhancer Activity of the Selected Motifs and Inter-
action with SR Proteins—The alternative splicing of pre-mRNA
involves the selection of a particular pair of 5- and 3-splice
sites from other possible combinations of potential splice sites
present in the same pre-mRNA. This process appears to be
largely facilitated by SR proteins that link the appropriate
splice sites in the early spliceosome (e.g. Ref. 18). From a very
complex pool of splicing enhancers, we have isolated a splicing
enhancer motif (GACGACCAGCAG) that stimulates exon in-
clusion and specifically interacts with SRp30. Two studies have
independently identified similar but shorter consensus
(RGACKACGAY, R  A/G, K  G/U, Y  C/U) in exonic
enhancers that are recognized by the SR protein 9G8 and
stimulate splicing of an upstream intron (26, 28). However, in
either case the role of the sequences adjacent to the consensus
in splicing enhancer activity or in binding with 9G8 has not
been characterized. Therefore, the consensus identified in
these studies may not represent the complete splicing enhanc-
ers, as the adjacent sequences obtained from selection were
also inserted in the pre-mRNAs when the enhancer activity
was assayed. In contrast, our approach allowed direct identifi-
cation of the complete enhancer motifs through systematic
comparison of a selectively amplified subpopulation of enhanc-
ers variegated in length. Although the enhancer motifs identi-
fied in our study are mostly symmetrical in contents, it is
apparent that the particular 5 and 3 sequences rather than
the symmetrical structure present in these motifs are essential
for splicing enhancer activity, because nucleotide substitutions
that either disrupted the original symmetrical structure or
created a new symmetrical sequence dramatically reduced
exon inclusion and abolished their interaction with SR proteins
(Figs. 3 and 4). In our preliminary experiments, the RNA probe
GACGACGA representing the 5 portion of our selected motif
was rapidly degraded in HeLa nuclear extract, indicating that
this sequence itself may not be sufficient to specifically interact
with any proteins (data not shown). We have also found that a
3 adjacent sequence AGCAGCAG is required for both splicing
enhancer activity and binding with SRp30, because replace-
ment of this sequence by the sequence at further downstream
of the exon abolished exon inclusion and binding with SRp30
(LP4.7RD, Fig. 3; LP4.7D, Fig. 4). Therefore, the 3 portion
AGCAG, although by itself shows a lack of enhancer activity in
the original DUP184 pre-mRNA, makes a significant contribu-
tion to the enhancer activity and therefore part of the enhancer
motif. We are not certain whether the SRp30 cross-linked with
the RNA probes in our study is 9G8. However, it is apparent
that although we and others have obtained a similar splicing
enhancer consensus, degenerate but particular 3 adjacent se-
quences are also required for enhancer activity and interaction
with SR proteins. The SRp30 observed in our study may par-
ticipate in the early spliceosome assembly through direct in-
teraction with the enhancer motifs of the pre-mRNAs and with
other general splicing factors, as depletion of the SRp30 from
the nuclear extract through affinity chromatography using the
enhancer motifs has dramatically reduced splicing activity
(data not shown). We are now characterizing particular pro-
teins purified by affinity chromatography tagged with the se-
lected enhancers, by protein mass spectrometry or microse-
quencing. This will allow us not only to identity the SRp30 but
also to find other associated general splicing factors in the early
spliceosome.
Although the purine-rich core GAGGAG is present in many
selected enhancers in our study (Fig. 2B), it is dispensable for
their splicing enhancer activity, as the absence of the purine-
rich core only slightly reduced exon inclusion (Fig. 3) and did
not abolish the cross-linking of the enhancer motif with SRp30
(Fig. 4). This is in contrast with observations by others in which
purine-rich GARGAR enhancers specifically interact with SR
proteins (e.g. Refs. 1, 7, 32). We conclude that the selected
enhancer motif (GACGACCAGCAG) largely contributes to
the splicing enhancer activity observed in our study.
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